These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 10662743)

  • 21. Coronary events with lipid-lowering therapy: the AFCAPS/TexCAPS trial. Air Force/Texas Coronary Atherosclerosis Prevention Study.
    Krut LH
    JAMA; 1999 Feb; 281(5):414; author reply 417-9. PubMed ID: 9952192
    [No Abstract]   [Full Text] [Related]  

  • 22. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).
    Girman CJ; Rhodes T; Mercuri M; Pyörälä K; Kjekshus J; Pedersen TR; Beere PA; Gotto AM; Clearfield M;
    Am J Cardiol; 2004 Jan; 93(2):136-41. PubMed ID: 14715336
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [AFCAPS/TexCAPS [The Air Force/Texas Coronary Atherosclerosis Prevention Study]].
    Goto Y
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():398-403. PubMed ID: 11347102
    [No Abstract]   [Full Text] [Related]  

  • 24. Coronary events with lipid-lowering therapy: the AFCAPS/TexCAPS trial. Air Force/Texas Coronary Atherosclerosis Prevention Study.
    Walsh J
    JAMA; 1999 Feb; 281(5):416-7; author reply 417-9. PubMed ID: 9952197
    [No Abstract]   [Full Text] [Related]  

  • 25. [Statins in primary prevention of coronary heart disease].
    Paulweber B
    Wien Med Wochenschr; 1999; 149(5-6):129-38. PubMed ID: 10408004
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lability of serum low-density lipoprotein cholesterol levels during screening in subgroup of Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) cohort.
    Clearfield MB; Weis SE; Willis JM; Vasenius KA; McConathy WJ
    J Am Osteopath Assoc; 2002 Jul; 102(7):377-84. PubMed ID: 12138952
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Coronary events with lipid-lowering therapy: the AFCAPS/TexCAPS trial. Air Force/Texas Coronary Atherosclerosis Prevention Study.
    Papadakis JA; Mikhailidis DP
    JAMA; 1999 Feb; 281(5):416; author reply 417-9. PubMed ID: 9952196
    [No Abstract]   [Full Text] [Related]  

  • 28. The effect of aggressive and moderate lowering of LDL-cholesterol and low dose anticoagulation on plasma lipids, apolipoproteins and lipoprotein families in post coronary artery bypass graft trial.
    Alaupovic P; Fesmire JD; Hunnighake D; Domanski M; Forman S; Knatterud GL; Forrester J; Herd JA; Hoogwerf B; Campeau L; Gobel FL
    Atherosclerosis; 1999 Oct; 146(2):369-79. PubMed ID: 10532693
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Coronary events with lipid-lowering therapy: the AFCAPS/TexCAPS trial. Air Force/Texas Coronary Atherosclerosis Prevention Study.
    McDiarmid TD; Hensel WA
    JAMA; 1999 Feb; 281(5):416; author reply 417-9. PubMed ID: 9952195
    [No Abstract]   [Full Text] [Related]  

  • 30. Effect of lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss: a post hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study.
    Kendrick J; Shlipak MG; Targher G; Cook T; Lindenfeld J; Chonchol M
    Am J Kidney Dis; 2010 Jan; 55(1):42-9. PubMed ID: 19932541
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Implications of Total to High-Density Lipoprotein Cholesterol Ratio Discordance With Alternative Lipid Parameters for Coronary Atheroma Progression and Cardiovascular Events.
    Elshazly MB; Nicholls SJ; Nissen SE; St John J; Martin SS; Jones SR; Quispe R; Stegman B; Kapadia SR; Tuzcu EM; Puri R
    Am J Cardiol; 2016 Sep; 118(5):647-55. PubMed ID: 27392507
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High--Density Lipoprotein Intervention Trial.
    Boden WE
    Am J Cardiol; 2000 Dec; 86(12A):19L-22L. PubMed ID: 11374850
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Coronary events with lipid-lowering therapy: the AFCAPS/TexCAPS trial. Air Force/Texas Coronary Atherosclerosis Prevention Study.
    Kandzari DE; Goldschmidt-Clermont PJ
    JAMA; 1999 Feb; 281(5):415; author reply 417-9. PubMed ID: 9952193
    [No Abstract]   [Full Text] [Related]  

  • 34. The ratio of apoB/apoAI, apoB and lipoprotein(a) are the best predictors of stable coronary artery disease.
    Rasouli M; Kiasari AM; Mokhberi V
    Clin Chem Lab Med; 2006; 44(8):1015-21. PubMed ID: 16879071
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Air Force/Texas Coronary Atherosclerosis Prevention Study: implications for preventive cardiology in the general adult US population.
    Whitney E
    Curr Atheroscler Rep; 1999 Jul; 1(1):38-43. PubMed ID: 11122690
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis.
    Boekholdt SM; Arsenault BJ; Mora S; Pedersen TR; LaRosa JC; Nestel PJ; Simes RJ; Durrington P; Hitman GA; Welch KM; DeMicco DA; Zwinderman AH; Clearfield MB; Downs JR; Tonkin AM; Colhoun HM; Gotto AM; Ridker PM; Kastelein JJ
    JAMA; 2012 Mar; 307(12):1302-9. PubMed ID: 22453571
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?
    Simes RJ; Marschner IC; Hunt D; Colquhoun D; Sullivan D; Stewart RA; Hague W; Keech A; Thompson P; White H; Shaw J; Tonkin A;
    Circulation; 2002 Mar; 105(10):1162-9. PubMed ID: 11889008
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular Disease.
    Welsh C; Celis-Morales CA; Brown R; Mackay DF; Lewsey J; Mark PB; Gray SR; Ferguson LD; Anderson JJ; Lyall DM; Cleland JG; Jhund PS; Gill JMR; Pell JP; Sattar N; Welsh P
    Circulation; 2019 Aug; 140(7):542-552. PubMed ID: 31216866
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lovastatin decreases de novo cholesterol synthesis and LDL Apo B-100 production rates in combined-hyperlipidemic males.
    Cuchel M; Schaefer EJ; Millar JS; Jones PJ; Dolnikowski GG; Vergani C; Lichtenstein AH
    Arterioscler Thromb Vasc Biol; 1997 Oct; 17(10):1910-7. PubMed ID: 9351353
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.
    Bonnet J; McPherson R; Tedgui A; Simoneau D; Nozza A; Martineau P; Davignon J;
    Clin Ther; 2008 Dec; 30(12):2298-313. PubMed ID: 19167589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.